Literature DB >> 16505157

In vitro and in vivo nuclear factor-kappaB inhibitory effects of the cell-penetrating penetratin peptide.

Tamás Letoha1, Erzsébet Kusz, Gábor Pápai, Annamária Szabolcs, József Kaszaki, Ilona Varga, Tamás Takács, Botond Penke, Erno Duda.   

Abstract

Penetratin is a cationic cell-penetrating peptide that has been frequently used for the intracellular delivery of polar bioactive compounds. Recent studies have just revealed the major role of polyanionic membrane proteoglycans and cholesterol-enriched lipid rafts in the uptake of the peptide. Both proteoglycans and lipid-rafts influence inflammatory processes by binding a wide array of proinflammatory mediators; thus, we decided to analyze the effect of penetratin on in vitro and in vivo inflammatory responses. Our in vitro luciferase gene assays demonstrated that penetratin decreased transcriptional activity of nuclear factor-kappaB (NF-kappaB) in tumor necrosis factor (TNF)-stimulated L929 fibroblasts and lipopolysaccharide-activated RAW 264.7 macrophages. Penetratin also inhibited TNF-induced intercellular adhesion molecule-1 expression in human endothelial HMEC-1 cells. Exogenous heparan sulfate abolished the in vitro NF-kappaB inhibitory effects of the peptide. Uptake experiments showed that penetratin was internalized by all of the above-mentioned cell lines in vitro and rapidly entered the cells of the lung and pancreas in vivo. In an in vivo rat model of acute pancreatitis, a disease induced by elevated activities of stress-responsive transcription factors like NF-kappaB, pretreatment with only 2 mg/kg penetratin attenuated the severity of pancreatic inflammation by interfering with IkappaB degradation and subsequent nuclear import of NF-kappaB, inhibiting the expression of proinflammatory genes and improving the monitored laboratory and histological parameters of pancreatitis and associated oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505157     DOI: 10.1124/mol.105.019653

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

Review 1.  Targeting antibodies to the cytoplasm.

Authors:  Andrea L J Marschall; André Frenzel; Thomas Schirrmann; Manuela Schüngel; Stefan Dübel
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

Review 2.  Cell-penetrating peptides and antimicrobial peptides: how different are they?

Authors:  Sónia Troeira Henriques; Manuel Nuno Melo; Miguel A R B Castanho
Journal:  Biochem J       Date:  2006-10-01       Impact factor: 3.857

3.  Immunological response to peptide nucleic acid and its peptide conjugate targeted to transactivation response (TAR) region of HIV-1 RNA genome.

Authors:  Alok Upadhyay; Nicholas M Ponzio; Virendra N Pandey
Journal:  Oligonucleotides       Date:  2008-12

4.  A cell-penetrating peptide suppresses inflammation by inhibiting NF-κB signaling.

Authors:  Yu Fu Wang; Xiang Xu; Xia Fan; Chun Zhang; Qiang Wei; Xi Wang; Wei Guo; Wei Xing; Jian Yu; Jing-Long Yan; Hua-Ping Liang
Journal:  Mol Ther       Date:  2011-05-10       Impact factor: 11.454

Review 5.  NSAIDs and Acute Pancreatitis: A Systematic Review.

Authors:  Raffaele Pezzilli; Antonio Maria Morselli-Labate; Roberto Corinaldesi
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-10

Review 6.  Suppression of TLR signaling by targeting TIR domain-containing proteins.

Authors:  Ota Fekonja; Monika Avbelj; Roman Jerala
Journal:  Curr Protein Pept Sci       Date:  2012-12       Impact factor: 3.272

Review 7.  Inhibition of regulated cell death by cell-penetrating peptides.

Authors:  Stefan Krautwald; Christin Dewitz; Fred Fändrich; Ulrich Kunzendorf
Journal:  Cell Mol Life Sci       Date:  2016-04-05       Impact factor: 9.261

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.